A preparation method of a traditional Chinese medicine composition for treating chronic idiopathic thrombocytopenia

Abstract

The application provides a preparation method of a traditional Chinese medicine composition for treating chronic primary thrombocytopenia, and relates to the technical field of traditional Chinese medicine compositions. The preparation method comprises the following steps: water extraction or alcohol extraction of Semen Euryae, Herba Epimedii, Radix Astragali, Radix Rehmanniae, Forsythia and Cinnamomum cassia, or water extraction of Radix Astragali and Radix Rehmanniae, and alcohol extraction of other medicinal materials, filtering, combining the filtrates, concentrating to a clear extract, adding excipients, drying, and whole-graining to obtain the traditional Chinese medicine composition; or directly crushing Cinnamomum cassia and Forsythia to obtain a medium powder, water extraction of other medicinal materials, filtering, combining the filtrates, concentrating to obtain a clear extract, adding the medium powder into the clear extract, stirring, drying, crushing, and adding excipients to obtain the traditional Chinese medicine composition. The traditional Chinese medicine composition prepared by the method can obviously reduce the bleeding grade of model mice, increase the platelet count of model mice, and can effectively treat chronic primary thrombocytopenia.

Description

Technical Field

[0001] This invention belongs to the field of traditional Chinese medicine composition technology, specifically relating to a method for preparing a traditional Chinese medicine composition for treating chronic primary thrombocytopenia. Background Technology

[0002] Primary immune thrombocytopenic purpura (ITP) is a condition caused by platelet counts below the normal range, and it is divided into acute (AITP) and chronic (CITP) types. Currently, clinical treatment for ITP primarily involves first-line therapy with hormones and gamma globulin, while second-line therapy often uses thrombopoietin-stimulating agents (TPO), platelet receptor agonists, monoclonal antibodies, and immunosuppressants. Splenectomy and platelet transfusion are also used clinically. Western medicine treatments are fast-acting and can alleviate symptoms to some extent, but the condition is prone to relapse, has significant side effects, and relapse is likely when the dosage is reduced or discontinued. Furthermore, the high cost of Western medicine limits its widespread use.

[0003] Traditional Chinese medicine (TCM) has a long history of treating hemorrhagic diseases, with relatively stable efficacy. It has certain advantages in preventing and treating bleeding, reducing the toxic side effects of Western medicine, and preventing relapse when reducing or withdrawing hormones. It can also achieve satisfactory results in cases where Western medicine treatment is ineffective. However, in the preparation of the medicine, traditional decoction methods often result in insufficient decoction of the medicinal materials, inconsistent standards, and resource waste, leading to increased use of ingredients and difficulty in ensuring uniform efficacy. Invention patent application CN101612286A discloses a TCM composition made from herbs such as Cynomorium songaricum, which has the effect of treating primary thrombocytopenic purpura. However, the efficacy of this TCM composition in treating primary thrombocytopenic purpura still needs to be improved. Invention patent application CN106728681A discloses a TCM composition for treating acute primary immune thrombocytopenic purpura and its preparation method. In this method, some of the raw medicinal materials are extracted with water to obtain an extract, and some of the raw medicinal materials are directly pulverized into powder. The extract and powder are mixed and granulated. This composition has many medicinal ingredients, and the single dose is relatively large. With the increasing demand for health, the development of medical science, and the improvement of diagnostic capabilities, more patients with immune thrombocytopenic purpura have been discovered. There is an urgent need for a method to prepare a safe, effective, stable, convenient, and low-dosage traditional Chinese medicine composition for the treatment of chronic primary thrombocytopenic purpura. Summary of the Invention

[0004] This invention addresses the problems of existing technologies in the treatment of chronic primary thrombocytopenic purpura, such as easy relapse, significant toxic side effects of Western medicine, easy relapse when reducing or discontinuing medication, ineffectiveness of hormone immunosuppressants such as gamma globulin and TPO in some cases, inconvenient administration of existing traditional Chinese medicine formulations, and large dosages. It provides a method for preparing a traditional Chinese medicine composition for treating chronic primary thrombocytopenic purpura. The composition obtained by this method can effectively treat chronic primary thrombocytopenic purpura, and is convenient to take with small dosages, making it more suitable for industrial transformation of pharmaceutical preparations.

[0005] A method for preparing a traditional Chinese medicine composition for treating chronic primary thrombocytopenia includes the following steps:

[0006] (A1) Weigh out the Chinese medicinal materials Cuscuta chinensis, Epimedium, Astragalus membranaceus, Rehmannia glutinosa, Forsythia suspensa and Cinnamomum cassia. Extract them with solvent in several batches, filter them, combine the filtrates, concentrate them, and obtain clear extract 1.

[0007] (A2) Add excipients to Qinggao 1, dry, and granulate to obtain the final product.

[0008] Preferably, the solvent in step (A1) is a water or ethanol solution.

[0009] More preferably, the concentration of the ethanol solution is 60%-90%.

[0010] Preferably, the amount of solvent added in step (A1) is 10-14 times the amount of the Chinese medicinal material.

[0011] Preferably, the extraction is performed 1-3 times in step (A1).

[0012] Preferably, the extraction time in step (A1) is 0.5-1 hour.

[0013] Preferably, the concentration in step (A1) is vacuum concentration.

[0014] More preferably, the vacuum concentration temperature is 50-75℃.

[0015] Preferably, in step (A1), the relative density of the ointment 1 at 60°C is 1.01-1.20.

[0016] Preferably, the excipients in step (A2) are selected from one or more of dextrin, maltodextrin, soluble starch and lactose.

[0017] Preferably, the drying in step (A2) is vacuum drying or spray drying.

[0018] More preferably, the reduced pressure drying temperature is 50-70℃.

[0019] More preferably, the spray drying inlet air temperature is 110-180℃, and the outlet air temperature is 80-120℃.

[0020] A method for preparing a traditional Chinese medicine composition for treating chronic primary thrombocytopenia includes the following steps:

[0021] (B1) Weigh out the Chinese medicinal materials Cuscuta chinensis, Epimedium, Forsythia suspensa and Cinnamomum cassia, extract with ethanol multiple times, filter, combine the filtrates, recover the ethanol, and obtain the alcohol extract;

[0022] (B2) Weigh out the raw Chinese medicinal materials Astragalus membranaceus and Rehmannia glutinosa, extract them with water multiple times, filter them, combine the filtrates, concentrate them, and obtain the water extract.

[0023] (B3) Combine the alcohol extract and water extract, concentrate, and obtain clear extract 2;

[0024] (B4) Add excipients to the clear paste 2, dry, and granulate to obtain the final product.

[0025] Preferably, in steps (B1) and (B2), the number of times extracted is selected from 1 to 3.

[0026] Preferably, in step (B1), the amount of ethanol added in a single extraction is 10-14 times the amount of the medicinal material, the extraction time is 0.5-1h, and the concentration of ethanol is 60%-90%.

[0027] Preferably, in step (B2), the amount of water added in a single extraction is 10-14 times the amount of the medicinal material, and the extraction time is 0.5-2 hours.

[0028] Preferably, the concentration in step (B3) is vacuum concentration.

[0029] More preferably, the vacuum concentration temperature is 50-75℃.

[0030] Preferably, in step (B3), the relative density of the ointment 2 at 60°C is 1.01-1.20.

[0031] Preferably, the excipients in step (B4) are selected from one or more of dextrin, maltodextrin, soluble starch and lactose.

[0032] Preferably, the drying in step (B4) is vacuum drying or spray drying.

[0033] More preferably, the reduced pressure drying temperature is 50-70℃.

[0034] More preferably, the spray drying inlet air temperature is 110-180℃, and the outlet air temperature is 80-120℃.

[0035] A method for preparing a traditional Chinese medicine composition for treating chronic primary thrombocytopenia, characterized in that the method comprises the following steps:

[0036] (C1) Weigh out the raw materials of Chinese medicinal herbs, cinnamon and forsythia, crush them, and sieve them to obtain medium powder;

[0037] (C2) Weigh out the Chinese medicinal materials Cuscuta chinensis, Epimedium brevicornu, Astragalus membranaceus and Rehmannia glutinosa, add water to extract them multiple times, filter them, combine the filtrates, concentrate them, and obtain clear extract 3;

[0038] (C3) Add the medium powder to the clear paste 3, stir, and dry to obtain dry paste powder;

[0039] (C4) The dry powder is pulverized and appropriate excipients are added to obtain the product.

[0040] Preferably, in step (C2), the amount of water added in a single extraction is 10-14 times the amount of the medicinal material, the number of extractions is 1-3, and the extraction time for a single extraction is 0.5-2 hours.

[0041] Preferably, the concentration in step (C2) is vacuum concentration.

[0042] More preferably, the vacuum concentration temperature is 50-75℃.

[0043] Preferably, in step (C2), the relative density of the ointment 3 at 60°C is 1.01-1.20.

[0044] Preferably, the drying in step (C3) is vacuum drying or spray drying.

[0045] More preferably, the reduced pressure drying temperature is 50-70℃.

[0046] More preferably, the spray drying inlet air temperature is 110-180℃, and the outlet air temperature is 80-120℃.

[0047] Preferably, the excipients in step (C4) are selected from one or more of dextrin, maltodextrin, soluble starch and lactose.

[0048] Preferably, the raw materials of traditional Chinese medicine are in the following weight parts: Cuscuta chinensis 100-500 parts, Epimedium brevicornu 100-500 parts, Astragalus membranaceus 100-500 parts, Rehmannia glutinosa 100-400 parts, Forsythia suspensa 100-400 parts, and Cinnamomum cassia 30-200 parts.

[0049] Preferably, the raw materials of traditional Chinese medicine are in the following weight parts: 100-400 parts of Cuscuta chinensis, 100-400 parts of Epimedium brevicornu, 100-400 parts of Astragalus membranaceus, 100-300 parts of Rehmannia glutinosa, 100-250 parts of Forsythia suspensa, and 30-150 parts of Cinnamomum cassia.

[0050] Preferably, the raw materials of traditional Chinese medicine are in the following weight parts: Cuscuta chinensis 150-500 parts, Epimedium brevicornu 150-500 parts, Astragalus membranaceus 150-500 parts, Rehmannia glutinosa 150-400 parts, Forsythia suspensa 100-400 parts, and Cinnamomum cassia 60-200 parts.

[0051] Preferably, the Chinese medicinal materials are in the following weight parts: Cuscuta chinensis 150-300 parts, Epimedium brevicornu 150-300 parts, Astragalus membranaceus 150-300 parts, Rehmannia glutinosa 150-300 parts, Forsythia suspensa 100-200 parts, and Cinnamomum cassia 40-100 parts.

[0052] Compared with the prior art, the present invention has the following beneficial effects: (1) The traditional Chinese medicine composition prepared by the preparation method of the present invention can improve the bleeding grade of model mice and increase the platelet count of model mice in pharmacological experiments; (2) The traditional Chinese medicine composition included in the preparation method of the present invention conforms to the principle of "principal, assistant, adjuvant and guide" in traditional Chinese medicine, can effectively control the bleeding symptoms of patients, improve the quality of life, increase the platelet count, and has a significant therapeutic effect on immune thrombocytopenia; (3) The traditional Chinese medicine composition obtained by the preparation method of the present invention is convenient to take, has a small dosage, and is suitable for industrial transformation. Detailed Implementation

[0053] The following embodiments are for illustrative purposes only and are not intended to limit the scope of protection of the invention. Those skilled in the art can make any alterations or modifications to the invention, and these equivalent changes and modifications also fall within the scope defined by the claims.

[0054] The pharmaceutical composition of Example 1 and its preparation method

[0055] The composition is as follows: 300g of Cuscuta chinensis, 300g of Epimedium brevicornu, 300g of Astragalus membranaceus, 200g of Rehmannia glutinosa, 200g of Forsythia suspensa, and 100g of Cinnamomum cassia.

[0056] The preparation method is as follows:

[0057] The raw materials of traditional Chinese medicine were extracted with an 80% ethanol solution at a ratio of 1:10. The extraction was performed twice, for 1 hour each time. The extract was filtered, and the ethanol was recovered from the filtrate under reduced pressure at 60°C. The extract was concentrated to a clear paste with a density of 1.1 (60°C). Maltodextrin was added, mixed well, spray-dried, and granulated to obtain the final product.

[0058] The pharmaceutical composition and its preparation method in Example 2

[0059] The composition is the same as in Example 1.

[0060] The preparation method is as follows:

[0061] The raw materials of traditional Chinese medicine were extracted with water at a ratio of 1:10, twice, for 1 hour each time. The extract was filtered, and the ethanol was recovered from the filtrate under reduced pressure at 65°C. The extract was concentrated to a clear paste with a density of 1.1 (60°C). Maltodextrin was added, mixed well, spray-dried, and granulated to obtain the final product.

[0062] The pharmaceutical composition and its preparation method in Example 3

[0063] The composition is the same as in Example 1.

[0064] The preparation method is as follows:

[0065] The raw medicinal materials Cuscuta chinensis, Epimedium brevicornu, Forsythia suspensa, and Cinnamomum cassia were extracted with 80% ethanol solution at a material-to-liquid ratio of 1:12, three times, 0.5 hours each time. The extract was filtered, and the filtrate was concentrated under reduced pressure at 60℃ to obtain an ethanol extract. The raw medicinal materials Astragalus membranaceus and Rehmannia glutinosa were extracted with water at a material-to-liquid ratio of 1:10, twice, 1 hour each time. The extract was filtered, and the filtrate was concentrated under reduced pressure at 60℃ to obtain an aqueous extract. The ethanol extract and aqueous extract were combined and concentrated under reduced pressure at 60℃ to a clear extract with a density of 1.1 (60℃). Maltodextrin was added to the clear extract, mixed well, spray-dried, and granulated to obtain the final product.

[0066] The pharmaceutical composition and its preparation method in Example 4

[0067] The composition is the same as in Example 1.

[0068] The preparation method is as follows:

[0069] The raw materials of Chinese medicinal herbs, cinnamon and forsythia, are pulverized and sieved to obtain a medium powder. The raw materials of Chinese medicinal herbs, dodder seed, epimedium, astragalus and rehmannia, are extracted with water at a ratio of 1:12, twice, for 1 hour each time. The extract is filtered, and the filtrate is concentrated under reduced pressure at 70°C to a clear extract with a density of 1.2 (60°C). The medium powder is added to the clear extract, stirred, and dried under reduced pressure at 60°C to obtain a dry extract powder. The dry extract powder is pulverized, soluble starch is added, and the powder is granulated to obtain the final product.

[0070] Test Example 1, Examples 1-4, Animal Experimental Studies

[0071] Objective: To investigate the effect of the test product on peripheral blood platelet count in mice after intraperitoneal injection of 1:4 APS by continuous gavage for 14 days in SPF-grade mice.

[0072] method:

[0073] Eighty SPF-grade healthy BALB / c mice were selected as test subjects, with an equal number of males and females, weighing 18-22g in total. All experimental animals were housed in the animal housing room of the experimental animal center after purchase.

[0074] Guinea pig anti-mouse platelet serum (APS) 1:4 was prepared in-house. (In week 1, a platelet suspension containing complete Freund's adjuvant was subcutaneously injected (sc) into at least four points on the paws, back, and abdomen of guinea pigs. In weeks 2, 3, 4, and 5, a platelet suspension containing incomplete Freund's adjuvant was injected subcutaneously into at least four points on the paws, back, and abdomen of guinea pigs, each time. The injection volume was 1 mL per animal. In week 6, non-anticoagulated whole blood was collected from the guinea pig heart and infused at 1800 rpm.) -1 After centrifugation for 10 min, collect the supernatant serum, which is guinea pig anti-mouse platelet antiserum (GP-APS). Store at -20℃ for later use. Take GP-APS, bring it to room temperature, and incubate at 56℃ for 30 min to inactivate complement. Add an equal volume of 5% BALB / c mouse erythrocyte suspension, incubate at 37℃ for 1 h, and reflux at 3000 rpm. -1 Centrifuge for 10 min and discard the precipitate. Add an equal volume of 5% BALB / c mouse erythrocyte suspension to the supernatant and incubate at 37°C for 1 h at 3000 rpm. -1 Centrifuge for 10 min, discard the precipitate, and the 1:4 GP-APS is prepared. Aliquot and store at -20℃.

[0075] BALB / c mice were randomly divided into four groups based on body weight and peripheral blood PLT count: a normal group (distilled water, 10 ml / kg), a model group (distilled water, 10 ml / kg), groups 1-4 (21.2 g crude drug / kg), a group treated with sweet potato leaf hemostatic compound (18.5 ml / kg), and a group treated with prednisolone acetate tablets (6.2 mg / kg), with 10 mice in each group, half male and half female. Except for the normal group, the other groups underwent intraperitoneal injection of 1:4 APS to induce the PLT model on days 1, 3, 5, 7, 9, 11, and 13, with each mouse receiving 0.1 ml (the normal group received 0.1 ml of physiological saline). Gavage administration began after the first injection and continued until day 14 post-modeling. All BALB / c mice were weighed every three days. 10 μL of blood was collected from the tail vein on days 5 and 14 after administration, and the PLT count in the peripheral blood was measured using an automated hematology analyzer. Experimental data were analyzed using Graphphad Prism 9.5 and SPSS 20.0 statistical software. Quantitative data were expressed as mean and standard deviation (s). t-tests were used to compare means between two groups, and variances were used to compare means among multiple groups. A p-value < 0.05 was considered statistically significant.

[0076] Results: All BALB / c mice were weighed every three days during the medication period, and there were no significant changes in body weight in any group. The number and statistical results of bleeding grades in each experimental group are shown in Table 1, and the results of the effect on platelets in immune thrombocytopenic purpura mice are shown in Table 2.

[0077] Table 1 Number of bleeding grades in each experimental group

[0078]

[0079] Note: Compared with the normal group, * This indicates that P < 0.05. ** This indicates that P < 0.01; compared with the model group, # This indicates that P < 0.05. ## This indicates P < 0.01; compared with the Golden Potato Leaf Hemostatic Mixture ▲ P < 0.05 ▲▲ P < 0.01.

[0080] In the bleeding grading experiment, no bleeding occurred in the normal group mice; however, in the model group mice and all drug groups, bleeding of varying degrees and in different locations appeared at 7 days, occurring on the face, ears, ankles, feet, and injection sites in the abdomen, with bleeding rates ranging from 40% to 90%. Compared with the normal group, the model group showed a significant difference in bleeding, indicating successful modeling. Compared with the model group, all drug-treated groups showed significant differences, all significantly reducing the grade and amount of bleeding. Compared with the *Polygonum multiflorum* leaf hemostatic compound, the drug effects of each embodiment were comparable to those of the *Polygonum multiflorum* leaf hemostatic compound.

[0081] Table 2 Effects on platelet count in mice with immune thrombocytopenic purpura.

[0082]

[0083] * Note: Compared with the normal group * This indicates that P < 0.05. ** This indicates P < 0.01; compared with the model group. # This indicates that P < 0.05. ## This indicates that P < 0.01, compared with the Golden Potato Leaf Hemostatic Mixture. ▲ This indicates that P < 0.05. ▲▲ This indicates that P < 0.01.

[0084] The results of the peripheral blood platelet count test showed that, compared with the blank control group, the platelet count in the model group was significantly reduced at 5 days and 14 days of administration (P<0.05), indicating successful modeling; compared with the model group, the platelet count in each administration group was significantly increased at 5 days and 14 days of treatment (P<0.05); compared with the Jinshuye compound, the therapeutic effects of the drugs in Examples 1-4 of this application on the mouse model were comparable to those of the Jinshuye compound.

[0085] Conclusion: The platelet count in the model group of BALB / c mice was significantly lower than that in the normal group, indicating the successful establishment of an immune thrombocytopenic purpura mouse model. During the experiment, there were no significant changes in the body weight of the mice in each group. No significant bleeding was observed in the normal group and the treated groups, while significant bleeding was observed in the model group. Compared with the model group, the platelet count in each treated group was significantly increased. The therapeutic effects of the drugs in Examples 1-4 of this application on the mouse model were comparable to those of prednisolone acetate and the compound of *Polygonum multiflorum* leaves.

[0086] The formula of the traditional Chinese medicine composition of this invention is based on the following: Cuscuta chinensis, which is pungent and sweet in taste and neutral in nature, enters the liver, spleen and kidney meridians, and nourishes the liver and kidneys, tonifying both yin and yang, serving as the principal herb; Epimedium brevicornu, which is warm and sweet in nature and enters the kidney meridian, tonifying the kidneys and transforming yang; Rehmannia glutinosa, which is sweet and bitter in taste and cold in nature, nourishes yin, tonifies the kidneys, clears heat and cools the blood, and when combined with Epimedium brevicornu and Cuscuta chinensis, it seeks yang within yin, tonifying both yin and yang, and restraining the damp-heat nature of Epimedium brevicornu and Cuscuta chinensis; Astragalus membranaceus, which is sweet and warm in nature, enters the spleen and lung meridians, strengthens the spleen and benefits qi, and tonifies and controls blood; Rehmannia glutinosa, Astragalus membranaceus, and Epimedium brevicornu together serve as the assistant herbs, assisting Cuscuta chinensis in tonifying the liver and kidneys; Forsythia suspensa, which is bitter and slightly cold in nature, enters the heart, lung and small intestine meridians, clears heat and prevents excessive heat, serving as the adjuvant herb; Cinnamomum cassia, which is pungent and sweet in taste and very hot in nature, tonifies fire and strengthens yang, and guides fire back to its source, serving as the messenger herb. The six herbs combined warm and tonify the spleen and kidneys, and are used for thrombocytopenic purpura and syndromes of spleen and kidney yang deficiency with lingering pathogenic factors.

[0087] Finally, it should be noted that the above content is only used to illustrate the technical solution of the present invention, and is not intended to limit the scope of protection of the present invention. Simple modifications or equivalent substitutions made by those skilled in the art to the technical solution of the present invention do not depart from the essence and scope of the technical solution of the present invention.

Claims

1. A method for preparing a traditional Chinese medicine composition for treating chronic idiopathic thrombocytopenia, characterized in that, The preparation method of the traditional Chinese medicine composition comprises the following steps: (A1) weigh the traditional Chinese medicine raw materials of Semen cuscutae, Herba epimedii, Radix paeoniae alba, Radix et Rhizoma breviscopic, and Fructus forsythiae and Cinnamomum cassia, and extract with solvent in several times, filter, combine the filtrates, concentrate, and obtain clear paste 1; (A2) add excipients to the clear paste 1, dry, and granulate, and the traditional Chinese medicine composition is obtained; wherein The traditional Chinese medicine raw materials comprise, by weight fraction: Semen cuscutae 100-500 parts, Herba epimedii 100-500 parts, Radix paeoniae alba 100-500 parts, Radix et Rhizoma breviscopic 100-400 parts, Fructus forsythiae 100-400 parts, and Cinnamomum cassia 30-200 parts; the extraction times are 1-3 times, the single solvent addition amount is 10-14 times the amount of the traditional Chinese medicine raw materials, and the single extraction time is 0.5-1 h; the solvent is water or an ethanol solution, and the concentration of the ethanol solution is 60%-90%.

2. The production method according to claim 1, characterized by, In the step (A1), the relative density of the clear paste 1 is 1.01-1.20 at 60 ℃.

3. A method for preparing a traditional Chinese medicine composition for treating chronic idiopathic thrombocytopenia, characterized in that, The preparation method of the traditional Chinese medicine composition comprises the following steps: (B1) weigh the traditional Chinese medicine raw materials of Semen cuscutae, Herba epimedii, Fructus forsythiae, and Cinnamomum cassia, extract with ethanol solution for multiple times, filter, combine the filtrates, recover ethanol, and obtain alcohol extract; (B2) weigh the traditional Chinese medicine raw materials of Radix paeoniae alba and Radix et Rhizoma breviscopic, extract with water for multiple times, filter, combine the filtrates, concentrate, and obtain water extract; (B3) combine the alcohol extract and the water extract, concentrate, and obtain clear paste 2; (B4) add excipients to the clear paste 2, dry, and granulate, and the traditional Chinese medicine composition is obtained; The traditional Chinese medicine raw materials comprise, by weight fraction: Semen cuscutae 100-500 parts, Herba epimedii 100-500 parts, Radix paeoniae alba 100-500 parts, Radix et Rhizoma breviscopic 100-400 parts, Fructus forsythiae 100-400 parts, and Cinnamomum cassia 30-200 parts; In the step (B1), the concentration of the ethanol is 60%-90%, the extraction times are 1-3 times, the single ethanol addition amount is 10-14 times the amount of the traditional Chinese medicine raw materials, and the single extraction time is 0.5-1 h; In the step (B2), the extraction times are 1-3 times, the single water addition amount is 10-14 times the amount of the traditional Chinese medicine raw materials, and the single extraction time is 0.5-2 h. The preparation method of the traditional Chinese medicine composition comprises the following steps:

4. A method for preparing a traditional Chinese medicine composition for treating chronic idiopathic thrombocytopenia, characterized in that, (C1) crush the traditional Chinese medicine raw materials of Cinnamomum cassia and Fructus forsythiae, sieve, and obtain medium powder; (C2) weigh the traditional Chinese medicine raw materials of Semen cuscutae, Herba epimedii, Radix paeoniae alba, and Radix et Rhizoma breviscopic, extract with water for multiple times, filter, combine the filtrates, concentrate, and obtain clear paste 3; (C3) add the medium powder to the clear paste 3, stir, and dry, and obtain dry paste powder; (C4) crush the dry paste powder, add appropriate excipients, and the traditional Chinese medicine composition is obtained; The traditional Chinese medicine raw materials comprise, by weight fraction: Semen cuscutae 100-500 parts, Herba epimedii 100-500 parts, Radix paeoniae alba 100-500 parts, Radix et Rhizoma breviscopic 100-400 parts, Fructus forsythiae 100-400 parts, and Cinnamomum cassia 30-200 parts; In the step (C2), the single water addition amount is 10-14 times the amount of the traditional Chinese medicine raw materials, the extraction times are 1-3 times, and the single extraction time is 0.5-2 h. ​ ​ 5. The method of any one of claims 1-4, wherein, The Chinese medicinal material raw materials are as follows in weight parts: Semen cuscutae 100-400 parts, Herba epimedii 100-400 parts, Radix paeoniae 100-400 parts, Radix rehmanniae 100-300 parts, Forsythia suspense 100-250 parts, Cinnamomum cassia 30-150 parts.

6. The method of any one of claims 1-4, wherein, The Chinese medicinal material raw materials are as follows in weight parts: Semen cuscutae 150-500 parts, Herba epimedii 150-500 parts, Radix paeoniae 150-500 parts, Radix rehmanniae 150-400 parts, Forsythia suspense 200-400 parts, Cinnamomum cassia 60-200 parts.

7. The method of any one of claims 1-4, wherein, The Chinese medicinal material raw materials are as follows in weight parts: Semen cuscutae 150-300 parts, Herba epimedii 150-300 parts, Radix paeoniae 150-300 parts, Radix rehmanniae 150-300 parts, Forsythia suspense 100-200 parts, Cinnamomum cassia 40-100 parts.

Images